Abstract
Bioactivity guided separation of combined n-hexane and chloroform extracts of Oplismenus burmannii resulted in the isolation and characterization of five new glycoglycerolipids, (2S)-1,2,6’-tri- O-hexadecanoyl-3-O-β-D-galactopyranosyl glycerol (1a), (2S)-1,2,6’-tri-O-[(9Z,12Z)-octadeca-9,12- dienoyl]-3-O-β-D-galactopyranosyl glycerol (1b), (2S)-1,6’-di-O-[(9Z,12Z)-octadeca-9,12-dienoyl]-3- O-β-D-galactopyranosyl glycerol (2b), (2S)-1,6’-di-O-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]-3-O-β-D-galactopyranosyl glycerol (2c), and (2S)-1,2-di-O-[(9Z,12Z)-octadeca-9,12-dienoyl]-3-O-(6- sulpho-α-D)-quinovopyranosyl glycerol (3b) along with five known glycoglycerolipids (1c, 2a, 3a, 3c and 4), a cerebroside (5), three monoacylglycerols (6a-c) and α-linoleic acid (7). The isolated compounds, 1-5 were in-vitro tested for their antihyperglycemic potential in terms of increase in 2-deoxyglucose uptake in L6-GLUT4myc myotube cells. The results showed that compounds, 1-5 were showing 1.52 (P<0.05), 1.50 (P<0.05), 1.28, 1.49 (P<0.05) and 1.50 (P<0.05) fold increase in the glucose uptake at concentration of 10 μg/mL and 1.71 (P<0.001), 1.74 (P<0.001), 1.50 (P<0.05), 1.76 (P<0.001) and 1.74 (P<0.001) fold increase in the glucose uptake at concentration of 25 μg/mL respectively. However, standard drug Rosiglitazone increases the glucose uptake by 1.59 fold at the concentration of 10μM. Further work on optimization of the anti-diabetic lead is under progress.
Keywords: Cerebroside, Glucose uptake, Glycoglycerolipids, L6-GLUT4myc myotube cells, Rosiglitazone.
Current Topics in Medicinal Chemistry
Title:Glycolipids: Isolated from Oplismenus burmannii Induce Glucose Uptake in L6-GLUT4myc Myotube Cells
Volume: 15 Issue: 11
Author(s): Surjeet Verma, Deepti Arha, Akhilesh Kumar Tamrakar and Santosh Kumar Srivastava
Affiliation:
Keywords: Cerebroside, Glucose uptake, Glycoglycerolipids, L6-GLUT4myc myotube cells, Rosiglitazone.
Abstract: Bioactivity guided separation of combined n-hexane and chloroform extracts of Oplismenus burmannii resulted in the isolation and characterization of five new glycoglycerolipids, (2S)-1,2,6’-tri- O-hexadecanoyl-3-O-β-D-galactopyranosyl glycerol (1a), (2S)-1,2,6’-tri-O-[(9Z,12Z)-octadeca-9,12- dienoyl]-3-O-β-D-galactopyranosyl glycerol (1b), (2S)-1,6’-di-O-[(9Z,12Z)-octadeca-9,12-dienoyl]-3- O-β-D-galactopyranosyl glycerol (2b), (2S)-1,6’-di-O-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]-3-O-β-D-galactopyranosyl glycerol (2c), and (2S)-1,2-di-O-[(9Z,12Z)-octadeca-9,12-dienoyl]-3-O-(6- sulpho-α-D)-quinovopyranosyl glycerol (3b) along with five known glycoglycerolipids (1c, 2a, 3a, 3c and 4), a cerebroside (5), three monoacylglycerols (6a-c) and α-linoleic acid (7). The isolated compounds, 1-5 were in-vitro tested for their antihyperglycemic potential in terms of increase in 2-deoxyglucose uptake in L6-GLUT4myc myotube cells. The results showed that compounds, 1-5 were showing 1.52 (P<0.05), 1.50 (P<0.05), 1.28, 1.49 (P<0.05) and 1.50 (P<0.05) fold increase in the glucose uptake at concentration of 10 μg/mL and 1.71 (P<0.001), 1.74 (P<0.001), 1.50 (P<0.05), 1.76 (P<0.001) and 1.74 (P<0.001) fold increase in the glucose uptake at concentration of 25 μg/mL respectively. However, standard drug Rosiglitazone increases the glucose uptake by 1.59 fold at the concentration of 10μM. Further work on optimization of the anti-diabetic lead is under progress.
Export Options
About this article
Cite this article as:
Verma Surjeet, Arha Deepti, Tamrakar Kumar Akhilesh and Srivastava Kumar Santosh, Glycolipids: Isolated from Oplismenus burmannii Induce Glucose Uptake in L6-GLUT4myc Myotube Cells, Current Topics in Medicinal Chemistry 2015; 15 (11) . https://dx.doi.org/10.2174/1568026615666150317223112
DOI https://dx.doi.org/10.2174/1568026615666150317223112 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein-Tyrosine Phosphatase 1B as a Potential Drug Target for Obesity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Metabolic Syndrome, Mild Cognitive Impairment and Dementia
Current Alzheimer Research Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease
Current Alzheimer Research Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued) Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Oxidative Stress Drivers and Modulators in Obesity and Cardiovascular Disease: From Biomarkers to Therapeutic Approach
Current Medicinal Chemistry Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Atomic Force Microscopy Study of Human Amylin (20-29) Fibrils
Protein & Peptide Letters The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis
Current Vascular Pharmacology Platelets: Their Potential Contribution to the Generation of Beta-amyloid Plaques in Alzheimer’s Disease
Current Neurovascular Research Editorial (Thematic Issue: Cognitive Dysfunction in Major Depressive Disorder - Pathophysiology, Clinical Implications and Treatment Opportunities)
CNS & Neurological Disorders - Drug Targets Molecular Basis of Inflammation and Insulin Resistance in Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Modulation of Energy Intake and Expenditure Due to Habitual Physical Exercise
Current Pharmaceutical Design Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
Current Pharmaceutical Design Endocrine Disrupting Chemical Induced “Pollution of Metabolic Pathways”: A Case of Shifting Paradigms With Implications for Vascular Diseases
Current Drug Targets Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Assessment of Cardiac Performance with Magnetic Resonance Imaging
Current Cardiology Reviews